Edition:
United Kingdom

Sinovac Biotech Ltd (SVA.OQ)

SVA.OQ on NASDAQ Stock Exchange Global Select Market

7.55USD
24 Sep 2018
Change (% chg)

$-0.31 (-3.94%)
Prev Close
$7.86
Open
$7.91
Day's High
$7.91
Day's Low
$7.55
Volume
3,503
Avg. Vol
10,967
52-wk High
$8.75
52-wk Low
$6.14

Latest Key Developments (Source: Significant Developments)

DOJ Closes Investigation Of Sinovac
Monday, 17 Sep 2018 

Sinovac Biotech Ltd ::DOJ CLOSES INVESTIGATION OF SINOVAC.SINOVAC BIOTECH LTD - WITH CLOSURE OF DOJ'S INVESTIGATION, NOT AWARE OF ANY PENDING U.S. GOVERNMENT INVESTIGATIONS OF CO RELATED TO THESE MATTERS.SINOVAC BIOTECH LTD - DOJ CLOSED INVESTIGATION INTO CO, WITH NO CHARGES, INTO POSSIBLE VIOLATIONS OF FOREIGN CORRUPT PRACTICES ACT.  Full Article

Vivo Capital Llc Dissolves Stake In Sinovac Biotech Ltd
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Sinovac Biotech Ltd ::VIVO CAPITAL, LLC DISSOLVES STAKE IN SINOVAC BIOTECH LTD AS OF AUG. 24 - SEC FILING.VIVO CAPITAL, LLC PREVIOUSLY REPORTED 6.6 PERCENT STAKE IN SINOVAC BIOTECH LTD AS OF JULY 19.  Full Article

Sinovac Raises $86.73 Mln Through Private Placement Transaction
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Sinovac Biotech Ltd ::SINOVAC RAISES $86.73 MILLION THROUGH PRIVATE PLACEMENT TRANSACTION.BOARD TERMINATES AMALGAMATION AGREEMENT TO TAKE COMPANY PRIVATE.VIVO CAPITAL & ADVANTECH CAPITAL EACH HOLD ABOUT 8.3% STAKE IN SINOVAC AFTER PRIVATE PLACEMENT TRANSACTION.VIVO CAPITAL AND ADVANTECH CAPITAL EACH RECEIVED A TOTAL OF 5.9 MILLION SINOVAC COMMON SHARES FOR $7.35 PER SHARE.SINOVAC BIOTECH - DECISION TO TERMINATE GOING-PRIVATE TRANSACTION WAS REACHED BY BOARD ON RECOMMENDATION OF INDEPENDENT SPECIAL COMMITTEE OF DIRECTORS.  Full Article

Sinovac Biotech Forced To Destroy Bacterial Seeds Intended For Production Of Vaccine
Monday, 30 Apr 2018 

April 30 (Reuters) - Sinovac Biotech Ltd ::SINOVAC BIOTECH - FORCED TO DESTROY BACTERIAL SEEDS INTENDED FOR USE IN PRODUCTION OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE.SINOVAC - FORCED TO SUSPEND PREPARATIONS FOR AND POSTPONE CHINA FDA INSPECTION OF MANUFACTURING SITE NEEDED FOR 23-VALENT PPV PRODUCTION APPROVAL.SINOVAC - DESTROYING BACTERIAL SEEDS, SUSPENDING PREPARATIONS FOR CFDA SITE INSPECTION TO DELAY COMMERCIALIZATION OF 23-VALENT PPV.  Full Article

Sinovac Announces Preliminary Results Of Phase Iii Trial On Sipv
Thursday, 19 Apr 2018 

April 19 (Reuters) - Sinovac Biotech Ltd ::SINOVAC ANNOUNCES PRELIMINARY RESULTS OF PHASE III TRIAL ON SIPV.SINOVAC BIOTECH - PRELIM RESULTS OF TRIAL AFTER UNBLINDING SHOW SEROCONVERSION RATE OF POLIOVIRUS TYPE II IS SUPERIOR TO CONTROL VACCINE.  Full Article

Sinovac Biotech Issues Statement In Response To Statements By Shandong Sinobioway Biomedicine Co Ltd
Wednesday, 18 Apr 2018 

April 18 (Reuters) - Shandong Sinobioway Biomedicine Co Ltd <002581.SZ>::SINOVAC BIOTECH LTD - ISSUES STATEMENT IN RESPONSE TO STATEMENTS BY SHANDONG SINOBIOWAY BIOMEDICINE CO LTD.SINOVAC BIOTECH LTD - SINOVAC BEIJING HAS NOT REFUSED TO PROVIDE FINANCIAL STATEMENTS REQUESTED BY SINOBIOWAY BIOMEDICINE CO LTD.SINOVAC BIOTECH LTD SAYS HAVE BEEN IN REGULAR COMMUNICATIONS WITH SINOBIOWAY REGARDING PLANNED TIMING OF COMPLETION OF ANNUAL AUDIT.  Full Article

Sinovac Biotech Receives Positive Decision On Hepatitis A Vaccine From WHO
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Sinovac Biotech Ltd ::SINOVAC BIOTECH RECEIVES POSITIVE DECISION ON ITS HEPATITIS A VACCINE FROM WORLD HEALTH ORGANIZATION.SINOVAC BIOTECH SAYS ‍RECEIVED POSITIVE DECISION FROM WHO ON ACCEPTABILITY OF HEALIVE, HEPATITIS A VACCINE , FOR PURCHASE BY UN AGENCIES​.  Full Article

Sinovac Biotech Announces Update On Nasdaq Matters
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Sinovac Biotech Ltd ::SINOVAC BIOTECH ANNOUNCES UPDATE ON NASDAQ MATTERS.SINOVAC BIOTECH- ‍NASDAQ HEARINGS PANEL GRANTED REQUEST TO EXTEND STAY OF SUSPENSION IN TRADING OF CO'S COMMON SHARES PENDING HEARING ON JAN 11, 2018​.  Full Article

Sinovac reports Q4 earnings per share $0.08
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Sinovac Biotech Ltd :Sinovac files 2016 annual report on form 20-F and reports unaudited fourth quarter 2016 financial results.Q4 earnings per share $0.08.Q4 sales rose 36.7 percent to $31.4 million.  Full Article

BRIEF-Sinovac Forced To Temporarily Suspend Flu Vaccine Production

* SINOVAC FORCED TO TEMPORARILY SUSPEND FLU VACCINE PRODUCTION DUE TO DISRUPTIVE ACTIONS TAKEN BY MINORITY SHAREHOLDER OF SINOVAC BEIJING